18.67
-0.58 (-3.01%)
| Previous Close | 19.25 |
| Open | 19.40 |
| Volume | 256,668 |
| Avg. Volume (3M) | 346,581 |
| Market Cap | 1,269,356,160 |
| Price / Sales | 4.51 |
| Price / Book | 19.73 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -0.990 |
| Total Debt/Equity (MRQ) | 7.24% |
| Current Ratio (MRQ) | 15.58 |
| Operating Cash Flow (TTM) | -40.08 M |
| Levered Free Cash Flow (TTM) | -19.59 M |
| Return on Assets (TTM) | -43.61% |
| Return on Equity (TTM) | -77.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Pulse Biosciences, Inc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.17 |
|
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 74.00% |
| % Held by Institutions | 8.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Griffin Asset Management, Inc. | 31 Dec 2025 | 226,312 |
| Brooklyn Investment Group | 31 Dec 2025 | 130,340 |
| Pandora Wealth, Inc. | 31 Dec 2025 | 51,452 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium |
| 04 Feb 2026 | Announcement | Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 |
| 03 Feb 2026 | Announcement | Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |